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IMPORTANCE Cannabis use is consistently linked to poorer mental health outcomes, and
there is evidence that use of higher-potency cannabis increases these risks. To date, no
studies have described the association between cannabis potency and concurrent mental
health in a general population sample or addressed confounding using longitudinal data.
OBJECTIVE To explore the association between cannabis potency and substance use and
mental health outcomes, accounting for precedingmental health and frequency of
cannabis use.
DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from the Avon Longitudinal
Study of Parents and Children, a UK birth cohort of participants born between April 1, 1991,
and December 31, 1992. Present data on outcomes and exposures were collected between
June 2015 and October 2017 from 1087 participants at 24 years of age who reported recent
cannabis use.
EXPOSURES Self-reported type of cannabis most commonly used in the past year, coded to
a binary exposure of use of high-potency cannabis or lower-potency cannabis.
MAIN OUTCOMES ANDMEASURES Outcomeswere reported frequency of cannabis use,
reported cannabis use problems, recent use of other illicit drugs, tobacco dependence,
alcohol use disorder, depression, generalized anxiety disorder, and psychotic-like
experiences. The study used secondary data; consequently, the hypotheses were formulated
after data collection.
RESULTS Past-year cannabis use was reported by 1087 participants (580women; mean [SD]
age at onset of cannabis use, 16.7 [3.0] years). Of these, 141 participants (13.0%) reported the
use of high-potency cannabis. Use of high-potency cannabis was associated with increased
frequency of cannabis use (adjusted odds ratio [AOR], 4.38; 95% CI, 2.89-6.63), cannabis
problems (AOR, 4.08; 95% CI, 1.41-11.81), and increased likelihood of anxiety disorder (AOR,
1.92; 95% CI, 1.11-3.32). Adjustment for frequency of cannabis use attenuated the association
with psychotic experiences (AOR 1.29; 95% CI, 0.67-2.50), tobacco dependence (AOR, 1.42;
95% CI, 0.89-2.27), and other illicit drug use (AOR, 1.29; 95% CI, 0.77-2.17). There was no
evidence of association between the use of high-potency cannabis and alcohol use disorder
or depression.
CONCLUSIONS AND RELEVANCE To our knowledge, this study provides the first general
population evidence suggesting that the use of high-potency cannabis is associated with
mental health and addiction. Limiting the availability of high-potency cannabis may be
associated with a reduction in the number of individuals who develop cannabis use disorders,
the prevention of cannabis use from escalating to a regular behavior, and a reduction in the
risk of mental health disorders.
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G lobally, cannabis is themost commonly used interna-tionally regulated drug,1 and policy on its use is be-comingmore liberalworldwide.2Theprimarypsycho-
active component of cannabis is Δ9-tetrahydrocannabinol
(THC). The potency (concentration of THC)may be an impor-
tant factor in the association between cannabis use andmen-
tal health. Experimental studies indicate that THC intoxica-
tion is dose dependent, with higher doses causing greater
memory impairment and transientpsychotic-like symptoms.3
Policy liberalizationhas beenaccompaniedbyproliferationof
high-potency cannabis in legal markets,4,5 and THC concen-
trations have increased in markets where cannabis remains
illegal.6
Cannabisuse is consistently linked topoorermentalhealth
outcomes,7,8 and there is evidence that higher-potency can-
nabis is associated with higher risks. A case-control study of
first-episode psychosis in England found that thosewho self-
reported using higher-potency cannabis were twice as likely
tohave apsychotic disorder, comparedwithparticipantswho
didnotusecannabis.9When the studywas replicated inamul-
tinational case-control studyof first-episodepsychosis across
11 sites inEurope andBrazil, the incidenceof psychosis across
sites was positively correlated with the prevalence of high-
potency cannabis use in the site-specific control samples.10 In
a self-selecting sampleofpeoplewhouse internationally regu-
lated drugs, the use of high-potency strains of cannabis was
associated with self-report of lifetime depression11 and can-
nabis dependence.12 These findings indicate that the avail-
ability of high-potency cannabismay increase risks of poorer
mental health, addiction, andneed for treatment among those
who are using the drug.
The strength of association between the use of cannabis
andmental health outcomes is increased when cannabis use
is frequent; consequently, increased frequencyofusemaycon-
found the association between cannabis potency andmental
health outcomes.12 Understanding the extent towhichharms
of high-potency cannabis are due to the THC content of the
drug, and the extent towhich these harmsmay be accounted
for by increased frequency of use, is important for informing
policy decisions around taxation and limits on drug potency.
To our knowledge, to date, no studies of the association
between cannabis potency andmental health have been con-
ducted in a general population sample. General population
studies can provide a valid estimate of the association be-
tween mental health outcomes and cannabis potency at the
population level, which may be crucial for informing policy
makers and clinical service providers. We use data from the
Avon Longitudinal Study of Parents and Children (ALSPAC),
a large general population birth cohortwhere contemporane-
ousdatawere collectedwhenparticipantswere24yearsof age
on cannabis potency, cannabis use frequency, and validated
measures of mental health outcomes, and prospective mea-
sures of adolescentmental healthwere collected frompartici-
pants up to 24 years of age.
The aims of our study were to (1) describe the use of dif-
ferent potencies of cannabis among a population of UK ado-
lescents; (2) explore the association between cannabis po-
tency and problems resulting from cannabis use, use and
disordered use of other substances, common mental disor-
ders, andpsychotic experiences (PEs) bycomparing thosewho
use high-potency cannabis with those who use lower po-
tency cannabis; and (3) determine the extent to which such
associations are explained by adolescent mental health at 12
to 13 years of age, age at onset of cannabisuse, andcurrent fre-
quency of cannabis use.
Methods
Study Population
ALSPAC is a UK population-based birth cohort, the methods
of which have previously been outlined13,14 (see eAppendix 1
in the Supplement for full details). The sample for the pre-
sent analyses comprised the 1087 participants who reported
on their past-year cannabis use while attending the ALSPAC
clinic between June 2015 andOctober 2017 at amean (SD) age
of24.0 (0.8) years (Figure 1).Dataon the2085 individualswho
participated in the assessment at 24 years of age but were ex-
cluded based on reporting no recent cannabis use are avail-
able in eTable 3 in the Supplement (see also eAppendix 1 in
the Supplement for further details on all the measures de-
scribed). Ethical approval for the studywasobtained from the
ALSPAC Ethics and Law Committee and the local Research
Ethics Committees. Written informed consent for the use of
datacollectedviaquestionnairesandclinicswasobtained from
participants following the recommendations of the ALSPAC
Ethics and Law Committee at the time.
Exposure
Thosewho reportedpast-year cannabis usewere asked“What
type of cannabis have you most commonly used or taken in
the last 12 months?” and were able to select from the follow-
ingoptions: “herbal cannabis/marijuana,” “skunk/other stron-
ger types of herbal cannabis,” “hashish/resin/solid,” “other,”
Key Points
Question Does use of high-potency cannabis (compared with use
of low-potency cannabis) increase risks for problems resulting
from cannabis use, commonmental disorders, and psychotic
experiences after controlling for early-life mental health symptoms
and frequency of use?
Findings In this cohort study of 1087 participants who reported
cannabis use in the previous year, after adjusting for frequency
of cannabis use and early adolescent mental health, use of
high-potency cannabis was associated with a significant increase
in the frequency of cannabis use, likelihood of cannabis problems,
and likelihood of anxiety disorder. Those using high-potency
cannabis had a small increase in the likelihood of psychotic
experiences; however, this risk was attenuated after adjustment
for frequency of cannabis use.
Meaning Risks for cannabis use problems and anxiety disorders
are higher among those reporting use of high-potency cannabis;
provision of public health messaging regarding the importance of
reducing both frequency of cannabis use and the potency of the
drug, as well as limiting the availability of high-potency cannabis,
may be effective for reducing these risks.
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or “don’t know.” Consistent with previous research that has
validated self-reporteddataon3 cannabis types against quan-
tifiedconcentrationsofTHCandcannabidiol amongyoungUK
cannabis users,15 we categorized cannabis as either high po-
tency (typically ≥10% THC; “skunk/other stronger types of
herbal cannabis”) or lowpotency (typically<10%THC;“herbal
cannabis/marijuana,” “hashish/resin/solid,” or “other”).10
Outcomes
Cannabis Use Frequency at 24 Years of Age
Participantswere asked“in the last 12months, howoftenhave
you used cannabis?” This variable was dichotomized to
“Monthly use or less” or “weekly/daily use.”
Problematic Cannabis Use at 24 Years of Age
Thosewhoself-reported2ormore itemsontheCannabisAbuse
Screening Test16 within the past year were classified as
having recently experienced problems associated with their
cannabis use.
Other Substance Use and Dependencies at 24 Years of Age
Participant self-report of theuse of any illicit drugs in thepast
12monthswas categorized as recent other illicit druguse. The
reference group was composed of those who reported no re-
cent use of these other illicit drugs (including those who had
neverused thesedrugs). Participantswerecategorizedasnico-
tine dependent if they self-reporteddaily nicotineuse and re-
ported 3 or more criteria on the Fagerström Test for Nicotine
Dependence,17 indicating low,medium,high,orveryhighnico-
tinedependence. The reference groupwas composedof those
whomet criteria for very lowdependenceand thosewhowere
notusingnicotine everydayorhadnever smoked. TheDSM-5
criteria for alcohol use disorder (AUD)18 were used to identify
participants experiencing alcohol use problems. Participants
were categorized as experiencing moderate or severe AUD if
they self-reported 4 or more of the AUD criteria. The refer-
ence group was composed of those who reported less than
4 of the AUD criteria (including individuals who had never
drunk alcohol).
Mental Health at 24 Years of Age
Participantscompletedaself-administeredcomputerizedClini-
cal Interview Schedule–revised,19 a tool for lay interviewers
to assess psychiatric disorders in the community. Partici-
pants who met the criteria for moderate or severe DSM-IV20
major depressive disorder at time of the interview were cat-
egorized as experiencing depression. Participants who met
DSM-IV criteria for generalized anxiety disorder20 were cat-
egorized as experiencing anxiety. Participants were rated on
PEs using the PLIKS (psychosis-like symptoms) semistruc-
tured interviewadministeredbytrainedresearchers.21,22Those
who were rated as having suspected or definite hallucina-
tions,delusions, or thought interference in thepast 12months,
whichwere either frequent (at leastmonthly) or caused them
distress (reportedasquitedistressingorverydistressing),were
classified as having had a recent PE. For the purposes of these
analyses, PEs were excluded if they happened only when the
participantwas either falling asleeporwakingup,was illwith
a high temperature, or within 2 hours of drinking alcohol or
taking drugs.
Covariates
ProspectiveMeasures From Early Childhood and Adolescence
Childhoodsocioeconomicpositionwasassessed throughmea-
sures from maternal questionnaires completed during preg-
nancy; variables were maternal educational attainment and
parents’ occupation class. A child’s racial/ethnic background
was derived from parents’ reported race/ethnicity (coded as
white or black andminority ethnic group).
Toaccount formental health symptomspreceding theon-
set of cannabis use (mean age at onset of cannabis use in
sample, 16.7years; 95%CI, 16.5-16.9years), a continuous score
measure of depression symptoms at 13 years of age was in-
cluded in analyses of major depressive disorder and general-
izedanxietydisorder.These symptomswereassessed through
theself-completedMoodandFeelingsQuestionnaireat 13years
of age,23 a tool formeasuringdepression in childrenandyoung
people. The number of PEs (assessed by PLIKS21) reported at
12 years of agewas included in the analysis of the outcome of
PEs at 24 years of age.
Age at onset of cannabis usewas self-reported in ALSPAC
at 14, 15, 16, 18, 20, 22, and 24 years of age. Participants who
reported lifetime use of cannabis at any of these points were
asked at what age they first used cannabis. Participants’ ear-
liest reportof ageat first cannabisusewasused toderiveavari-
able of age at onset of cannabis use.
Statistical Analysis
All analyseswere conducted in Stata, version 15.1 (StataCorp).
Theassociationbetweenuseofhigh-potencycannabisandsub-
stance use andmental health at 24 years of age was analyzed
using univariable and multivariable logistic regression, with
cannabis potency as the independent variable. Three sepa-
ratemultivariablemodelswere performed for each outcome:
Figure 1. FlowDiagram Showing the Avon Longitudinal Study
of Parents and Children Analysis Sample
13 988 Offspring alive at 1 y
9295 Participants invited to attend interview at 24 y
3727 Participants attending follow-up at mean age 24 y
1087 Participants reported using cannabis in past 12 mo
4693 Excluded because not alive, no
current address available, or
withdrawn from study
5568 Excluded because did not respond
or did not attend interview
2640 Excluded because did not report
past-year cannabis use at 24 y
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(1) adjusting for sex and childhood socioeconomic position;
(2) additional adjustment for age at onset of cannabis use for
modelsof substanceuseoutcomes,depressionsymptomscore
at 13 years of age formodels ofmajor depressive disorder and
generalized anxiety disorder outcomes, and PEs at 12 years of
age for the model with PE as the outcome (time points se-
lected to ensure mental health symptoms preceded onset of
cannabis use); and (3) adjusted as in model 2, with inclusion
of a categoricalmeasure of cannabis use frequency. Thismea-
sure allowed estimation of the extent to which preexisting
symptomsofmentalhealthdisordersandthe frequencyofcan-
nabis use explained any association between the use of high-
potency cannabis and substance use and mental health out-
comes.Results arepresentedasodds ratios (ORs)with95%CIs.
Propensity score models were applied to complete case data
as a sensitivity test (eAppendix 2 and eTables 1 and 2 in the
Supplement).
Missing Data and Imputation
As outcomes and exposureswere collected at the samepoint,
most missing data were in the covariates assessed at earlier
ages (eAppendix 1 and eTable 3 in the Supplement). Missing
data in all analysis variables (exposures, outcomes, and co-
variates) were addressed through multiple imputation using
chained equations, which uses a series of univariate regres-
sion models to impute each incomplete variable sequen-
tially. Eachmodel included all other analysis variables, along
with the following auxiliary variables: race/ethnicity, experi-
encing bullying up to 16 years of age, parental separation up
to 16 years of age, parental mental health problems up to
16 years of age, parental substance use up to 16 years of age,
Mood and Feelings Questionnaire score at 16 and 18 years of
age, number of self-reported psychotic-like experiences at 14
years of age, and conduct disorder symptoms up to 13 years
of age. Estimates were obtained by pooling results across 40
imputed data sets using the Rubin rules, and assessment of
MonteCarlo variability confirmed this as a suitable number of
imputations.24
Results
Of the 1087participants reportingpast-year cannabisuse at 24
years of age, 12.8% (number estimated from imputed propor-
tions) reported theuseofhigh-potency cannabis (Table 1). Use
of lower-potency forms of cannabis was reported by 87.2%
(number estimated from imputed proportions) of those who
used cannabis in thepast year (see eTable 3 in the Supplement
for data on this and on all analysis variables). Use of high-
potency cannabis was more common than use of lower-
potencycannabis in thosewhoweremale (71.6%vs43.3%)and
thosewho reported regular cannabis use (56.8%vs 17.6%), re-
centcannabisuseproblems (10.1%vs0.8%), recentuseofother
illicit drugs (82.9% vs 66.5%), tobacco dependence (37.0% vs
15.1%),AUD (15.1%vs 10.0%), depression (11.7%vs9.7%), gen-
eralized anxiety disorder (19.1% vs 11.6%), and PE (12.4% vs
7.1%) (Table 1).
Cannabis Use Outcomes
Therewas anunadjusted associationbetween theuseofhigh-
potency cannabis and frequency of cannabis use at 24 years
of age (OR, 6.21; 95%CI, 4.24-9.11) (Table 2). This association
was attenuated by adjustment for sociodemographic factors
and by the age at onset of cannabis use, but those reporting
use of high-potency cannabis remainedmore than 4 times as
likely to report using cannabis at least weekly comparedwith
those reporting use of lower-potency forms of cannabis (ad-
justed OR [AOR], 4.38; 95% CI, 2.89-6.63). There was also an
unadjusted associationbetween theuse of high-potency can-
nabis and reporting recent cannabis problems (OR, 13.17; 95%
CI, 5.41-32.04). This association was attenuated by adjust-
ment for age at onset of cannabis use and frequency of can-
Table 1. Association Between Type of Cannabis and Demographic, Substance Abuse,
andMental Health Outcomes in 1087 ParticipantsWho Reported Recent Cannabis Use
Characteristic
Cannabis use, %a
P valueb
High potency
(n = 141)
Lower potency
(n = 946)
Regular cannabis use 56.8 17.6 ≤.001
Cannabis use problems 10.1 0.8 ≤.001
Use of other illicit drugs 82.9 66.5 ≤.001
Tobacco dependence 37.0 15.1 ≤.001
Alcohol use disorder 15.1 10.0 ≤.001
Major depression (moderate or severe symptoms) 11.7 9.7 ≤.001
Generalized anxiety disorder 19.1 11.6 ≤.001
Psychotic-like experiences 12.4 7.1 ≤.001
Male sex 71.6 43.4 ≤.001
Low maternal educational level 19.2 13.1 ≤.001
Lower parental occupational class 32.2 29.2 ≤.001
Black or minority ethnic group 5.3 5.3 .94
Age at onset of cannabis use, mean (95% CI), y 14.7 (14.3-15.1) 16.9 (16.8-17.2) NA
MFQ score at 13 y, mean (95% CI) 5.6 (4.65-6.49) 5.6 (5.26-5.95) NA
No. PEs at 12 y, mean (95% CI) 0.33 (0.18-0.48) 0.20 (0.16-0.24) NA
Abbreviations: MFQ, Mood and
Feelings Questionnaire; NA, not
applicable; PEs, psychotic
experiences.
a All numbers estimated from
imputed proportions.
bDetermined by χ2 test.
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nabis use, but people reporting the use of high-potency can-
nabis were still more than 4 times as likely to report having
recently experienced problems associated with their canna-
bis use (AOR, 4.08; 95% CI, 1.41-11.81) (Table 2 and Figure 2).
Substance Use Outcomes
Those who reported the use of high-potency cannabis were
more than twice as likely to report recent use of other illicit
drugs within the past 12months (OR, 2.47; 95% CI, 1.53-3.97)
andmore than 3 times as likely to report tobacco dependence
(OR, 3.31; 95%CI, 2.23-4.92) (Table2). Theseassociationswere
largely attenuated by adjustment for sociodemographic fac-
tors, age at cannabis onset, and frequencyof cannabis use (re-
centuseof other illicit drugs:AOR, 1.29; 95%CI,0.77-2.17; and
tobaccodependence:AOR, 1.42;95%CI,0.89-2.27). Therewas
little evidence of an elevation in the likelihood of AUDamong
participantswho reporteduse of high-potency cannabis after
adjustment forsociodemographicvariables,ageatonsetofcan-
nabis use, and frequency of cannabis use (AOR, 0.90; 95%CI,
0.49-1.64) (Table 2 and Figure 2).
Mental Health Outcomes
Depression was slightly more common in the high-potency
cannabis group, but there was little statistical evidence that
highpotencywas associatedwithdepression (AOR, 1.28; 95%
CI, 0.68-2.34) (Table 2). There was evidence that use of high-
potency cannabis was associated with a moderate elevation
in likelihoodof generalizedanxietydisorder (OR, 1.77; 95%CI,
1.09-2.86). The strength of this association was increased
slightly after adjustment for sociodemographic variables, de-
pression symptoms at 14 years of age, and frequency of can-
nabis use (AOR, 1.92; 95% CI, 1.11-3.32).
Participants reporting the use of high-potency cannabis
werealmost twiceas likely to report frequentordistressingPEs
(OR, 1.81; 95%CI, 1.01-3.24) (not occurring directly after drug
use) (Table 2). However, evidence of association was weak-
enedafteradjustment for frequencyofcannabisuse (AOR, 1.29;
95% CI, 0.67-2.50) (Table 2 and Figure 2).
Discussion
The present study restricts analyses to individuals who have
used different forms of cannabis to inform understanding of
the implications of the proliferation of high-potency canna-
bis in legalmarkets.4,5 Inageneral population sampleofyoung
people in the UK, individuals who use high-potency canna-
bis (compared with those using lower-potency forms of can-
nabis)aremore likely tobeusingcannabis regularly,more likely
Figure 2. Fully Adjusted Associations Between the Use
of High-Potency Cannabis and Outcomes
103 51 110.4 
Odds Ratio
Outcome
Alcohol use disorder
Anxiety disorder
Depression
Psychotic experiences
Cannabis use problems
Use of other illicit drugs
Tobacco dependence
Including fully adjusted associations for sociodemographics, longitudinal mental
health, and frequency of use (seeMethods). The horizontal bars indicate 95%
CIs, and the dotted vertical line indicates the comparator group (individuals
who reported use of lower-potency cannabis).
Table 2. Logistic Regression Analysis of the Association Between High-Potency Cannabis and Substance Use andMental Health Outcomesa
Outcome
variable
Univariable OR
(95% CI) P value
Adjusted for childhood
sociodemographic
factors, AOR (95% CI) P value
Adjusted for
prospective mental
health measures,
AOR (95% CI) P value
Adjusted for
frequency of
cannabis use,
AOR (95% CI) P value
Regular cannabis
use
6.21 (4.24-9.11) ≤.001 5.81 (3.90-8.65) ≤.001 4.38 (2.89-6.63)b ≤.001 NA NA
Recent cannabis
use problems
13.17
(5.41-32.04)
≤.001 13.52 (5.28-34.60) ≤.001 8.45 (3.04-23.50)b ≤.001 4.08 (1.41-11.81) .009
Recent use of
other illicit drugs
2.47 (1.53-3.97) ≤.001 2.19 (1.35-3.56) .002 1.50 (0.91-2.49)b .11 1.29 (0.77-2.17) .34
Tobacco
dependence
3.31 (2.23-4.92) ≤.001 3.30 (2.18-4.99) ≤.001 2.05 (1.31-3.19)b .002 1.42 (0.89-2.27) .14
Alcohol use
disorder
1.60 (0.94-2.73) .08 1.49 (0.86-2.56) .15 0.99 (0.56-1.76)b .97 0.90 (0.49-1.64) .73
Major depression
(moderate
or severe
symptoms)
1.24 (0.70-2.18) .46 1.61 (0.89-2.93) .12 1.54 (0.84-2.82)c .16 1.28 (0.68-2.32) .44
Generalized
anxiety disorder
1.77 (1.09-2.86) .02 2.35 (1.41-3.92) ≤.001 2.28 (1.36-3.83)c .002 1.92 (1.11-3.32) .02
Psychotic-like
experiences
1.81 (1.01-3.24) .047 2.03 (1.10-3.73) .02 1.86 (1.00-3.46)d .05 1.29 (0.67-2.50) .45
Abbreviations: AOR, adjusted odds ratio; NA, not applicable; OR, odds ratio.
a All results estimated from imputed data. Multivariable model adjustment is
incremental.
bAge at onset of cannabis use.
c Depression symptom score at 13 years of age.
dNumber of psychotic experiences at 12 years of age.
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to reporthavingrecentlyexperiencedproblemsassociatedwith
their cannabis use, and more likely to concurrently be expe-
riencing use of other illicit drugs, tobacco dependence, AUD,
generalizedanxietydisorder, andPEs.After adjustment forage
at onset of cannabis use or for early adolescent measures of
psychopathologic conditions and frequency of cannabis use,
high-potency cannabis was associated with increases in the
likelihood of frequent cannabis use, having recently experi-
enced problems associated with cannabis use, and the likeli-
hood of experiencing generalized anxiety disorder. The re-
sults provide a profile of individuals who use high-potency
cannabis, indicating that thisbehavior ismorecommonamong
individuals who are male, grow up in families with a low so-
cioeconomic status, experience early PEs, and report early-
onset cannabis use.
Theoutcomes regarding substanceuse andmental health
mayreflect sharedpredisposing risk factors that couldalso lead
people toselect themostpotentdrugavailable.25As thesample
excluded those who had not used cannabis, increases in risk
for mental health outcomes associated with the use of high-
potency cannabis are unlikely to be conflated by a shared
liability todruguseandmentalhealthdisorders.However, evi-
dence shows that shared risk factors underlie both exposure
to cannabis andprogression todevelopmentofdependence.26
The profile of substance use outcomes and early-life experi-
ences among thosewhousehigh-potency cannabis in thepre-
sent study indicates that there may be overlapping risk fac-
torsbetweendevelopmentof substanceuseandmentalhealth
disorders and the selection of higher-potency forms of can-
nabis. We have sought to adjust for these factors, but further
considerationof the roleof cannabispotency in thecausalpath
to mental health disorders is warranted.
The estimate in the present study for the likelihoodof de-
pression among those using high-potency cannabis is similar
to estimates observed in a previous study of a self-selecting
sampleofdrug-usingparticipants (OR, 1.18;95%CI, 1.11-1.25).11
However, the estimate in the present studydemonstrating an
increase in the likelihood of generalized anxiety disorder
among thoseusinghigh-potency cannabis is in contrast to the
negligible increase in likelihood of lifetime anxiety disorder
observed in a previous study (OR, 1.05; 95% CI, 0.98-1.12).11
This discrepancymaybebecause theprevious study reliedon
self-reported lifetime diagnosis,11 whereas the present study
used DSM-IV–validatedmeasures of depression and general-
ized anxiety disorder at the time of assessment. A recent sys-
tematic review has indicated that cannabis use in adoles-
cence is associated with an increased likelihood of lifetime
depression and anxiety,8 although few studies had consid-
ered the potency or frequency of cannabis use.
A better understanding of the association between po-
tencyandfrequencyofcannabisuse is requiredtogainaclearer
understandingof the independentassociationofpotencywith
mental health. We found similar effect sizes for the associa-
tion between the use of high-potency cannabis and report of
frequent or distressing PEs (not associated with drug use) as
those observed in case-control studies of first-episode
psychosis.9,10 However, in our study, we observed a substan-
tial attenuation in effect size, by approximately 66%, after ad-
justment for frequency of cannabis use. The present findings
oncannabisproblemsand frequencyofuseareconsistentwith
previous evidence for a positive association between days of
use of high-potency cannabis and severity of dependence.12
In this previous study there was a linear association between
number of days of high-potency cannabis use permonth and
severity of dependence score (β = 0.15; 95% CI, 0.02-0.28).
Increased frequencyof cannabis use couldplausibly cause in-
dividuals to use higher-potency cannabis through the devel-
opment of tolerance to the effects of cannabis; if so, then it is
appropriate to consider cannabisuse frequencyasaconfound-
ing factor in the association with mental health. However, if
the use of higher-potency cannabis leads to increased fre-
quency of use, plausibly through high-potency cannabis de-
liveringTHCmore efficiently than lower-potency cannabis, it
would bemore appropriate to explore themediating effect of
cannabis frequency.
Strength and Limitations
This study has some strengths. To our knowledge, this study
is the first to describe the association between cannabis po-
tency and concurrentmental health and substance abuse in a
generalpopulationsample,andthefirst touse longitudinaldata
to address confoundingbyearlymental health symptomsand
age at onset of cannabis use in this association.
This study also has some limitations. First, given that the
data were collected in the context of an illegal cannabis mar-
ket, we cannot be certain participants are accurately in-
formed about the potency of the cannabis they are using. It is
plausible that the ability to identify type of cannabis is higher
amongthose frequentlyusing thedrug,althoughevidencesug-
gests that frequency of use does not moderate the associa-
tionbetween self-reported identificationof cannabis typeand
actual THC concentration in young UK cannabis users.15
Second, the exposures and outcomes that we examined
were cross-sectional. Because questions on the type of can-
nabis used were only asked at 24 years of age, it is plausible
that thepresenceof anxietydisorder orPEshave led to theuse
ofhigh-potencycannabis at 24yearsof age.Adjusting formea-
sures of psychopathologic conditions in adolescencehad little
effect on our estimates.
Third, recent use of high-potency cannabis was reported
byonly 12.8%of participants,whichmay result in someof the
analyses being underpowered (eTable 3 in the Supplement).
Fourth, as a result of attritionwithinALSPAC, thosewho took
part in thewave of the study that took place at 24 years of age
were more likely to be white, female, andmore affluent than
the population from which the participants were originally
drawn.14 In addition, because there is a dearth of nationally
representativedataonthedemographicsof thosewhousecan-
nabis, we cannot be certain the present sample is representa-
tive of the population of cannabis users in the UK or globally.
The analyses would benefit from replication in larger, repre-
sentative samples, but to our knowledge, ALSPAC is the only
longitudinal general population sample to include measures
of cannabis potency. Characteristics of those who did not re-
port cannabis use at 24 years of age are in eTable 4 in the
Supplement.
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Conclusions
The use of high-potency cannabis may occur as part of a pro-
file of other illicit drug use and substance dependency, likely
owing to shared risk factors underlying these behaviors and
the selection of high-potency strains. The present study sug-
gests that risks for cannabis use problems and anxiety disor-
ders are further increased among those reporting the use of
high-potency cannabis, even after accounting for sociodemo-
graphic factors, adolescent mental health, and frequency of
cannabisuse. Providingpublichealthmessaging regarding the
importanceof reducingboth the frequencyofcannabisuseand
the potency of the drug, as well as limiting the availability of
high-potencycannabis,maybeeffective for reducingtheharms
associated with cannabis use.
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